April 26, 2024
Loading...
You are here:  Home  >  'Thousand Oaks'  -  Page 54
Latest

Managed growth balances economic, environmental concerns

By   /  Friday, November 3rd, 2017  /  Columns, Latest news  /  Comments Off on Managed growth balances economic, environmental concerns

Henry Dubroff

This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.

Latest

Amgen launches second trial for Alzheimer’s product

By   /  Thursday, November 2nd, 2017  /  Health Care & Life Science, Latest news  /  Comments Off on Amgen launches second trial for Alzheimer’s product

Amgen and Novartis launched a second trial for a product intended to delay or prevent Alzheimer’s disease, in partnership with the Banner Alzheimer’s Institute. The biotech giant based in Thousand Oaks had previously collaborated on the first study in the Alzhiemer’s Prevention Initiative Generation program, which enrolled participants who had two copies of the apolipoprotein Read More →

Latest

Increased sales at Teledyne boost net income

By   /  Thursday, November 2nd, 2017  /  Earnings, Latest news, Technology, Tri-County Public Companies  /  Comments Off on Increased sales at Teledyne boost net income

Sales for Thousand Oaks-based Teledyne rose more than 25 percent for the third quarter of 2017, boosting net income up 32.7 percent to $69 million, or $1.90 per diluted share. Aerospace and defense electronics sales rose 7.6 percent for the company, and engineered systems sales increased nearly 10 percent to $73.1 million. Sales in the Read More →

Latest

Amgen buying out joint venture Kirin-Amgen for $780 million

By   /  Tuesday, October 31st, 2017  /  Health Care & Life Science, Latest news, Technology  /  Comments Off on Amgen buying out joint venture Kirin-Amgen for $780 million

Amgen, the biotech giant based in Thousand Oaks, announced that it would buy out joint venture Kirin-Amgen, which was created to develop white blood cell booster Neupogen among other projects, for $780 million. The joint venture holds intellectual property rights for Neupogen, Neulasta, Aranesp, Nplate and brodalumab. In addition to the cash deal, Amgen will Read More →

Latest

Amgen product sales slip but income stays steady

By   /  Thursday, October 26th, 2017  /  East Ventura County, Health Care & Life Science, Latest news, Tri-County Economy, Tri-County Public Companies  /  Comments Off on Amgen product sales slip but income stays steady

Net income at biotech giant Amgen stayed flat for the third quarter, despite a slight downtick in revenues to $5.8 billion, the company reported Oct. 25. Product sales saw a slight decline, including Neupogen, Epogen and its blockbuster rheumatoid arthritis drug Enbrel, which fell 6 percent, but net income stayed steady at a little more Read More →

Latest

Ventura County economic development plan approved

By   /  Tuesday, October 24th, 2017  /  East Ventura County, Latest news, Tri-County Economy, West Ventura County  /  Comments Off on Ventura County economic development plan approved

Ventura County’s Board of Supervisors has approved the first economic development plan in the history of the county. The board voted 5-0 to approve the countywide “Economic Vitality Strategic Plan” at its board meeting on Oct. 24. Officials said the plan was the product of four public sessions and was designed to “foster economic growth Read More →

Latest

Biotech giant Amgen to pay dividend on Dec. 8

By   /  Tuesday, October 24th, 2017  /  Earnings, Health Care & Life Science, Latest news, Technology, Tri-County Public Companies  /  Comments Off on Biotech giant Amgen to pay dividend on Dec. 8

Biotech giant Amgen announced Oct. 24 that it would pay a $1.15 dividend for its fourth quarter of fiscal 2017. Stockholders of record for the Thousand Oaks-based company at the end of day on Nov. 17 will receive the dividend on Dec. 8.